Clindamycin / Dalacin 15 mg/ml Text automatically translated in your browsing language Automatically translated

The target of the procurement is Dalacin 15 mg/ml, 80ml granules for oral solution. This is a one-time purchase and the product will be used by the rescEU Medical project in Finland. In addition to the estimated quantity, THL has the right to purchase 300% of the product in addition to the estimated quantity ("Option"). The total value of the acquisition is EUR 300,000 including Options. The procuring entity procures a medicinal product as a direct procurement in accordance with the Act on Public Contracts from a selected supplier. Following an in-depth market consultation carried out by the contracting entity, the outcome of the study was that there is only one authorised oral suspension medicinal product containing clindamycin, marketed in the EU/EEA under the name Dalacin1. The marketing authorisation holder of the product is Pfizer Oy. The product will be purchased directly for the rescEU warehouse, as there are currently no other compliant products or substitutes on the market. The absence of competition is not the result of an artificial narrowing down of the terms of the contract. Text automatically translated in your browsing language Automatically translated

33600000 - Pharmaceutical products

33651100 - Antibacterials for systemic use